{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:12:50Z","timestamp":1783930370408,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00228-026-04092-w","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:20:49Z","timestamp":1781137249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of carboplatin-based versus cisplatin-based chemotherapy in muscle-invasive and advanced bladder cancer: A systematic review and meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"given":"Jiahao","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"4092_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L (2024) Advances in diagnosis and treatment of bladder cancer. BMJ 384:e076743. https:\/\/doi.org\/10.1136\/bmj-2023-076743","journal-title":"BMJ"},{"key":"4092_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194891","volume":"13","author":"J-F Xiao","year":"2021","unstructured":"Xiao J-F, Caliri AW, Duex JE, Theodorescu D (2021) Targetable pathways in advanced bladder cancer: FGFR signaling. Cancers Basel 13:4891. https:\/\/doi.org\/10.3390\/cancers13194891","journal-title":"Cancers Basel"},{"key":"4092_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","volume":"22","author":"EY Yu","year":"2021","unstructured":"Yu EY, Petrylak DP, O\u2019Donnell PH et al (2021) Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2011201): a multicentre, single-arm, phase 2 trial. Lancet Oncol 22:872\u2013882. https:\/\/doi.org\/10.1016\/S1470-2045(21)00094-2","journal-title":"Lancet Oncol"},{"key":"4092_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.hoc.2021.02.011","volume":"35","author":"C Thibault","year":"2021","unstructured":"Thibault C, Loriot Y (2021) Emerging Targeted Therapy for Bladder Cancer. Hematol Oncol Clin North Am 35:585\u2013596. https:\/\/doi.org\/10.1016\/j.hoc.2021.02.011","journal-title":"Hematol Oncol Clin North Am"},{"key":"4092_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071795","volume":"14","author":"J Thomas","year":"2022","unstructured":"Thomas J, Sonpavde G (2022) Molecularly targeted therapy towards genetic alterations in advanced bladder cancer. Cancers Basel 14:1795. https:\/\/doi.org\/10.3390\/cancers14071795","journal-title":"Cancers Basel"},{"key":"4092_CR6","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s11864-022-01009-4","volume":"23","author":"J Peng","year":"2022","unstructured":"Peng J, Sridhar S, Siefker-Radtke AO et al (2022) Targeting the FGFR pathway in urothelial carcinoma: the future is now. Curr Treat Options Oncol 23:1269\u20131287. https:\/\/doi.org\/10.1007\/s11864-022-01009-4","journal-title":"Curr Treat Options Oncol"},{"key":"4092_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(19)30668-0","volume":"21","author":"DP Petrylak","year":"2020","unstructured":"Petrylak DP, de Wit R, Chi KN et al (2020) Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol 21:105\u2013120. https:\/\/doi.org\/10.1016\/S1470-2045(19)30668-0","journal-title":"Lancet Oncol"},{"key":"4092_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.hoc.2021.01.005","volume":"35","author":"JL Pfail","year":"2021","unstructured":"Pfail JL, Small AC, Cumarasamy S, Galsky MD (2021) Real World Outcomes of Patients with Bladder Cancer: Effectiveness Versus Efficacy of Modern Treatment Paradigms. Hematol Oncol Clin North Am 35:597\u2013612. https:\/\/doi.org\/10.1016\/j.hoc.2021.01.005","journal-title":"Hematol Oncol Clin North Am"},{"key":"4092_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.hoc.2021.02.010","volume":"35","author":"R Nadal","year":"2021","unstructured":"Nadal R, Clara JA, Valderrama BP, Bellmunt J (2021) Current therapy for metastatic urothelial carcinoma. Hematol Oncol Clin North Am 35:469\u2013493. https:\/\/doi.org\/10.1016\/j.hoc.2021.02.010","journal-title":"Hematol Oncol Clin North Am"},{"key":"4092_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","volume":"52","author":"L Dogliotti","year":"2007","unstructured":"Dogliotti L, Carten\u00ec G, Siena S et al (2007) Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52:134\u2013141. https:\/\/doi.org\/10.1016\/j.eururo.2006.12.029","journal-title":"Eur Urol"},{"key":"4092_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.eururo.2022.05.002","volume":"82","author":"AO Siefker-Radtke","year":"2022","unstructured":"Siefker-Radtke AO, Cho DC, Diab A et al (2022) Bempegaldesleukin plus Nivolumab in first-line metastatic urothelial carcinoma: results from PIVOT-02. Eur Urol 82:365\u2013373. https:\/\/doi.org\/10.1016\/j.eururo.2022.05.002","journal-title":"Eur Urol"},{"key":"4092_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1200\/JCO.2004.02.152","volume":"22","author":"A Bamias","year":"2004","unstructured":"Bamias A, Aravantinos G, Deliveliotis C et al (2004) Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. Journal of Clinical Oncology 22:220\u2013228. https:\/\/doi.org\/10.1200\/JCO.2004.02.152","journal-title":"Journal of Clinical Oncology"},{"key":"4092_CR13","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/cncr.20123","volume":"100","author":"R Dreicer","year":"2004","unstructured":"Dreicer R, Manola J, Roth BJ et al (2004) Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100:1639\u20131645. https:\/\/doi.org\/10.1002\/cncr.20123","journal-title":"Cancer"},{"key":"4092_CR14","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","volume":"10","author":"PJ Loehrer","year":"1992","unstructured":"Loehrer PJ, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Journal of Clinical Oncology 10:1066\u20131073. https:\/\/doi.org\/10.1200\/JCO.1992.10.7.1066","journal-title":"Journal of Clinical Oncology"},{"key":"4092_CR15","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"CN Sternberg","year":"2001","unstructured":"Sternberg CN, de Mulder PH, Schornagel JH et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol 30924. J Clin Oncol Off J Am Soc Clin Oncol 19:2638\u20132646. https:\/\/doi.org\/10.1200\/JCO.2001.19.10.2638","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4092_CR16","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1200\/JCO.22.02763","volume":"41","author":"H von der Maase","year":"2023","unstructured":"von der Maase H, Hansen SW, Roberts JT et al (2023) Gemcitabine and Cisplatin versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol Off J Am Soc Clin Oncol 41:3881\u20133890. https:\/\/doi.org\/10.1200\/JCO.22.02763","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4092_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364\u2013378. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.025","journal-title":"Eur J Pharmacol"},{"key":"4092_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","volume":"12","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J et al (2011) A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 12:211\u2013214. https:\/\/doi.org\/10.1016\/S1470-2045(10)70275-8","journal-title":"Lancet Oncol"},{"key":"4092_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/cncr.22454","volume":"109","author":"MD Galsky","year":"2007","unstructured":"Galsky MD, Iasonos A, Mironov S et al (2007) Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 109:549\u2013555. https:\/\/doi.org\/10.1002\/cncr.22454","journal-title":"Cancer"},{"key":"4092_CR20","unstructured":"The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/16342065\/. Accessed 20 May 2026"},{"key":"4092_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/sonc.2001.22537","volume":"28","author":"J Carles","year":"2001","unstructured":"Carles J, Nogu\u00e9 M (2001) Gemcitabine\/carboplatin in advanced urothelial cancer. Semin Oncol 28:19\u201324. https:\/\/doi.org\/10.1053\/sonc.2001.22537","journal-title":"Semin Oncol"},{"key":"4092_CR22","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.2001.19.9.2527","volume":"19","author":"M Hussain","year":"2001","unstructured":"Hussain M, Vaishampayan U, Du W et al (2001) Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19:2527\u20132533. https:\/\/doi.org\/10.1200\/JCO.2001.19.9.2527","journal-title":"J Clin Oncol"},{"key":"4092_CR23","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1200\/JCO.1998.16.5.1844","volume":"16","author":"BG Redman","year":"1998","unstructured":"Redman BG, Smith DC, Flaherty L et al (1998) Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16:1844\u20131848. https:\/\/doi.org\/10.1200\/JCO.1998.16.5.1844","journal-title":"J Clin Oncol"},{"key":"4092_CR24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/annonc\/mdr156","volume":"23","author":"MD Galsky","year":"2012","unstructured":"Galsky MD, Chen GJ, Oh WK et al (2012) Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 23:406\u2013410. https:\/\/doi.org\/10.1093\/annonc\/mdr156","journal-title":"Ann Oncol"},{"key":"4092_CR25","unstructured":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/22162575\/. Accessed 20 May 2026"},{"key":"4092_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/23523735251335122","volume":"11","author":"T Yanagisawa","year":"2025","unstructured":"Yanagisawa T, Matsukawa A, Teoh J-C et al (2025) Advancements in systemic therapy for muscle-invasive bladder cancer: a systematic review from the beginning to the latest updates. Bladder Cancer 11:23523735251335122. https:\/\/doi.org\/10.1177\/23523735251335122","journal-title":"Bladder Cancer"},{"key":"4092_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"4092_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. https:\/\/doi.org\/10.1186\/1745-6215-8-16","journal-title":"Trials"},{"key":"4092_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJNM, Welton NJ (2012) Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9","journal-title":"BMC Med Res Methodol"},{"key":"4092_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ (2021) IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol 21:111. https:\/\/doi.org\/10.1186\/s12874-021-01308-8","journal-title":"BMC Med Res Methodol"},{"key":"4092_CR31","unstructured":"RoB 2 a revised tool for assessing risk of bias in randomised trials - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/31462531\/. Accessed 20 May 2026"},{"key":"4092_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"19971115","key":"4092_CR33","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/(sici)1097-0142","volume":"80","author":"J Bellmunt","year":"1997","unstructured":"Bellmunt J, Ribas A, Eres N et al (1997) Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80(19971115):1966\u20131972. https:\/\/doi.org\/10.1002\/(sici)1097-0142. )80:10%3C1966::aid-cncr14%3E3.0.co;2-w","journal-title":"Cancer"},{"key":"4092_CR34","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/annonc\/mdu204","volume":"25","author":"CM Booth","year":"2014","unstructured":"Booth CM, Siemens DR, Peng Y et al (2014) Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice. Ann Oncol 25:1783\u20131788. https:\/\/doi.org\/10.1093\/annonc\/mdu204","journal-title":"Ann Oncol"},{"key":"4092_CR35","unstructured":"Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/8625244\/. Accessed 20 May 2026"},{"key":"4092_CR36","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00345-023-04408-w","volume":"41","author":"DJ Reesink","year":"2023","unstructured":"Reesink DJ, van Melick HHE, van der Nat PB et al (2023) Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer. World J Urol 41:1551\u20131562. https:\/\/doi.org\/10.1007\/s00345-023-04408-w","journal-title":"World J Urol"},{"key":"4092_CR37","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.euf.2021.08.009","volume":"8","author":"A Richters","year":"2022","unstructured":"Richters A, Boormans JL, van der Heijden MS et al (2022) Overall survival of patients receiving cisplatin or carboplatin for primary metastatic urothelial carcinoma of the bladder: a contemporary Dutch nationwide cohort study. Eur Urol Focus 8:995\u20131002. https:\/\/doi.org\/10.1016\/j.euf.2021.08.009","journal-title":"Eur Urol Focus"},{"key":"4092_CR38","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.1016\/j.clgc.2016.12.025","volume":"15","author":"AG Robinson","year":"2017","unstructured":"Robinson AG, Wei X, Vera-Badillo FE et al (2017) Palliative chemotherapy for bladder cancer: treatment delivery and outcomes in the general population. Clin Genitourin Cancer 15:e535\u2013e541. https:\/\/doi.org\/10.1016\/j.clgc.2016.12.025","journal-title":"Clin Genitourin Cancer"},{"key":"4092_CR39","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s00345-022-04160-7","volume":"40","author":"SMH Einerhand","year":"2022","unstructured":"Einerhand SMH, Black AJ, Zargar H et al (2022) Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. World J Urol 40:2707\u20132715. https:\/\/doi.org\/10.1007\/s00345-022-04160-7","journal-title":"World J Urol"},{"key":"4092_CR40","unstructured":"Carboplatin based induction chemotherapy for nonorgan confined bladder cancer\u2013a reasonable alternative for cisplatin unfit patients? - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/22901581\/. Accessed 20 May 2026"},{"key":"4092_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.euros.2023.02.014","volume":"51","author":"M von Deimling","year":"2023","unstructured":"von Deimling M, Mertens LS, van Rhijn BWG et al (2023) Carboplatin induction chemotherapy in clinically lymph node-positive bladder cancer. Eur Urol Open Sci 51:39\u201346. https:\/\/doi.org\/10.1016\/j.euros.2023.02.014","journal-title":"Eur Urol Open Sci"},{"key":"4092_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/jjco\/hys213","volume":"43","author":"K Iwasaki","year":"2013","unstructured":"Iwasaki K, Obara W, Kato Y et al (2013) Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer. Jpn J Clin Oncol 43:193\u2013199. https:\/\/doi.org\/10.1093\/jjco\/hys213","journal-title":"Jpn J Clin Oncol"},{"key":"4092_CR43","doi-asserted-by":"publisher","first-page":"589","DOI":"10.21037\/tau-2024-662","volume":"14","author":"K Nakane","year":"2025","unstructured":"Nakane K, Okamoto A, Kato H et al (2025) Significance of split-dose cisplatin-based neoadjuvant chemotherapy followed by robotic-assisted radical cystectomy for muscle invasive bladder cancer. Transl Androl Urol 14:589\u2013601. https:\/\/doi.org\/10.21037\/tau-2024-662","journal-title":"Transl Androl Urol"},{"key":"4092_CR44","doi-asserted-by":"publisher","unstructured":"K M, S T, K Y et al (2025) Outcomes of sequential therapy for advanced upper tract urothelial cancer and bladder cancer. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-025-25906-4","DOI":"10.1038\/s41598-025-25906-4"},{"key":"4092_CR45","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.37349\/etat.2024.00274","volume":"5","author":"MW Hwang","year":"2024","unstructured":"Hwang MW, Kauffeld J, Belay S et al (2024) Upper tract urothelial cancer (UTUC) genomic profiling and correlation regarding benefit of platinum-based chemotherapy. Explor Target Anti-tumor Ther 5:1261\u20131270. https:\/\/doi.org\/10.37349\/etat.2024.00274","journal-title":"Explor Target Anti-tumor Ther"},{"key":"4092_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10873-y","volume":"10","author":"BD Robinson","year":"2019","unstructured":"Robinson BD, Vlachostergios PJ, Bhinder B et al (2019) Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun 10:2977. https:\/\/doi.org\/10.1038\/s41467-019-10873-y","journal-title":"Nat Commun"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04092-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04092-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04092-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:57:21Z","timestamp":1783929441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04092-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4092"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04092-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (systematic review and meta-analysis).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}